Dr. Korman is currently Senior Vice President of Human Immunology at Vir Biotechnology, San Francisco, CA. Previously, he was Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy Prior to BMS, he held various positions at Medarex. His tenure at BMS and Medarex led to the development of two approved drugs for oncology, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) and their combination, which initiated the approach of checkpoint blockade. Relatlimab (anti-LAG-3) and a variety of other antibodies to immuno-oncology targets were also developed.
Dr. Korman received his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He was also a staff scientist at the Institut Pasteur prior to moving to the biotechnology sector.